Preliminary Evidence Suggests Feasibility of Early Immunotherapy Cessation in Metastatic Melanoma
Investigators reviewed the clinical outcomes of patients with metastatic melanoma who electively discontinued PD-1 inhibitor therapy at 1 year.
Investigators reviewed the clinical outcomes of patients with metastatic melanoma who electively discontinued PD-1 inhibitor therapy at 1 year.